ReShape Lifesciences Inc. reported Impairment of long-lived assets for the third quarter ended September 30, 2023. For the quarter, the company reported Impairment of long-lived assets of $777,000 against $7,429,000 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.22 USD | +7.63% |
|
+10.02% | -15.10% |
03:57pm | ReShape Signs Merger Agreement With Vyome, Asset Sale Deal With Biorad; Shares Rise | MT |
May. 15 | ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-15.10% | 4.79M | |
-0.27% | 205B | |
+3.29% | 178B | |
+31.07% | 158B | |
+31.95% | 112B | |
+1.79% | 64.58B | |
+22.32% | 55.34B | |
-3.27% | 46.64B | |
-10.31% | 36.78B | |
-1.17% | 34.85B |
- Stock Market
- Equities
- RSLS Stock
- News ReShape Lifesciences Inc.
- ReShape Lifesciences Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2023